Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs

被引：8
|
作者：
Lu, Xuemin [1 ]
Lu, Xin [1 ,2 ]
机构：
[1] Univ Notre Dame, Boler Parseghian Ctr Rare & Neglected Dis, Harper Canc Res Inst, Dept Biol Sci, Notre Dame, IN 46556 USA
[2] Indiana Univ, Tumor Microenvironm & Metastasis Program, Melvin & Bren Simon Comprehens Canc, Indianapolis, IN 46202 USA
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2022年 / 1877卷 / 03期
基金：
美国国家卫生研究院;
关键词：
Prostate cancer; Renal cell carcinoma; Bladder cancer; Penile cancer; Penile squamous cell carcinoma; Polymorphonuclear myeloid-derived suppres; sor cell; Immunotherapy; CXCR2; Reactive nitrogen species; SUPPRESSOR-CELLS; MYELOID CELLS; IMMUNOTHERAPY; PROMOTES; INHIBITION;
D O I：
10.1016/j.bbcan.2022.188702
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Immune checkpoint blockade (ICB) as a powerful immunotherapy has transformed cancer treatment. The application of ICB to genitourinary malignancies has generated substantial clinical benefits for patients with advanced kidney cancer or bladder cancer, yet very limited response to ICB therapy was observed from metastatic castration-resistant prostate cancer. The efficacy of ICB in rare genitourinary tumors (e.g. penile cancer) awaits results from ongoing clinical trials. A potential barrier for ICB is tumor-infiltrating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) with their functions and mechanisms recently revealed. Preclinical studies suggest that successful therapeutic inhibition of PMN-MDSCs synergizes effectively with ICB to eradicate ICB-refractory genitourinary malignancies.
引用
收藏
页数：8
相关论文
共 50 条
  • [31] Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
    Palakurthi, Bhavana
    Fross, Shaneann R.
    Guldner, Ian H.
    Aleksandrovic, Emilija
    Liu, Xiyu
    Martino, Anna K.
    Wang, Qingfei
    Neff, Ryan A.
    Golomb, Samantha M.
    Lewis, Cheryl
    Peng, Yan
    Howe, Erin N.
    Zhang, Siyuan
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
  • [32] Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy
    Ebelt, Nancy D.
    Zuniga, Edith
    Marzagalli, Monica
    Zamloot, Vic
    Blazar, Bruce R.
    Salgia, Ravi
    Manuel, Edwin R.
    [J]. BIOMEDICINES, 2020, 8 (12) : 1 - 20
  • [33] Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer
    Lu, Guowen
    Qiu, Yier
    Su, Xiaobao
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 157
  • [34] Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
    Bhavana Palakurthi
    Shaneann R. Fross
    Ian H. Guldner
    Emilija Aleksandrovic
    Xiyu Liu
    Anna K. Martino
    Qingfei Wang
    Ryan A. Neff
    Samantha M. Golomb
    Cheryl Lewis
    Yan Peng
    Erin N. Howe
    Siyuan Zhang
    [J]. Nature Communications, 14
  • [35] Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
    Zhong, Pingshan
    Nakata, Kohei
    Oyama, Koki
    Higashijima, Nobuhiro
    Sagara, Akiko
    Date, Satomi
    Luo, Haizhen
    Hayashi, Masataka
    Kubo, Akihiro
    Wu, Chenyi
    He, Shan
    Yamamoto, Takeo
    Koikawa, Kazuhiro
    Iwamoto, Chika
    Abe, Toshiya
    Ikenaga, Naoki
    Ohuchida, Kenoki
    Morisaki, Takashi
    Oda, Yoshinao
    Kuba, Keiji
    Nakamura, Masafumi
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [36] Targeting Syk reprograms tumor-associated macrophages and enhances responses to immune checkpoint blockade and radiation therapy in high-risk neuroblastoma
    Rohila, Deepak
    Park, In Hwan
    Pham, Timothy
    Jones, Riley
    Tamayo, Pablo
    Yu, Alice
    Sharabi, Andrew
    Joshi, Shweta
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [37] Cancer-targeting Antibody-sialidase Conjugate Reverses Polarization of Tumor-associated Macrophage and Improves Immune Checkpoint Blockade Therapy
    Shigehiro, Tsukasa
    [J]. TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY, 2023, 35 (204) : E28 - E28
  • [38] Preclinical characterization and efficacy of 4R9, a novel immune checkpoint blockade targeting CEACAM1 for cancer therapy.
    Lee, Jae-Chul
    Hur, Minkyu
    Park, Hye-Young
    Lee, EunHee
    Yum, Hye In
    Nam, Hye-mi
    Oh, Mi-Young
    Choi, HyundSuk
    Kim, Jae-Hwan
    Cho, Byoung Chul
    Lim, Yang-Mi
    Won, Jonghwa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
    Sun, Kai
    Xu, Yitian
    Zhang, Licheng
    Niravath, Polly
    Darcourt, Jorge
    Patel, Tejal
    Teh, Bin S.
    Farach, Andrew M.
    Guerrero, Carlo
    Mathur, Sunil
    Sultenfuss, Mark A.
    Gupta, Nakul
    Schwartz, Mary R.
    Haley, Susan L.
    Nair, Sindhu
    Li, Xiaoxian
    Nguyen, Thi Truc Anh
    Butner, Joseph D.
    Ensor, Joe
    Mejia, Jaime A.
    Mei, Zhuyong
    Butler, E. Brian
    Chen, Shu-Hsia
    Bernicker, Eric H.
    Chang, Jenny C.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (20) : 4392 - 4401
  • [40] Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study
    Molina, Gabriel E.
    Allen, Ian M.
    Hughes, Michael S.
    Zubiri, Leyre
    Lee, Hang
    Mooradian, Meghan J.
    Reynolds, Kerry L.
    Dougan, Michael
    Chen, Steven T.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (03) : 743 - 746
12345